Might the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle and reconsider the “all applicants” approach?
Research output: Other contribution › Net publication - Internet publication › Communication
The Broad Institute is facing a formidable task in defending the revoked CRISPR patent claims in their pending appeal at the EPO. Ultimately, some of the issues might still be referred to the Enlarged Board of Appeal. However, this might require a significant amount of legal and rhetorical agility.
| Original language | English |
|---|---|
| Publication date | Jul 2018 |
| Publisher | Harvard Law School's Bill of Health blog |
| Publication status | Published - Jul 2018 |
ID: 199590381